BAP Ex-Officio Member Details
Editor-in-Chief of BAP Journal of Psychopharmacology
Professor David Nutt
Imperial College London
David Nutt is currently the Edmund J Safra Professor of Neuropsychopharmacology and Head of the Centre for Neuropsychopharmacology in the Division of Brain Science, Dept of Medicine, Hammersmith Hospital, Imperial College London. He is also visiting professor at the Open University in the UK and Maastricht University in the Netherlands.
After 11+ entry to Bristol Grammar he won an Open Scholarship to Downing College Cambridge, then completed his clinical training at Guy's Hospital London. After a period in neurology to MRCP he moved to Oxford to a research position in psychiatry at the MRC Clinical Pharmacology Unit where he obtained his DM. On completing his psychiatric training in Oxford, he continued there as a lecturer and then later as a Wellcome Senior Fellow in psychiatry. He then spent two years as Chief of the Section of Clinical Science in the National Institute of Alcohol Abuse and Alcoholism in NIH, Bethesda, USA. He returned to England in 1988 to set up the Psychopharmacology Unit in Bristol University, an interdisciplinary research grouping spanning the departments of Psychiatry and Pharmacology before moving to Imperial College London in December 2008 where he leads a similar group with a particular focus on brain imaging especially PET.
He is currently President of the European Brain Council and Chair of the Independent Scientific Committee on Drugs (ISCD) and Past-President of the British Neuroscience Association. In addition he is a Fellow of the Royal Colleges of Physicians, of Psychiatrists and of the Academy of Medical Sciences. He is also the UK Director of the European Certificate and Masters in Affective Disorders Courses and a member of the International Centre for Science in Drug Policy. He has edited the Journal of Psychopharmacology for over fifteen years and acts as the psychiatry drugs advisor to the British National Formulary. He has published over 400 original research papers, a similar number of reviews and books chapters, eight government reports on drugs and 27 books including one for the general public Drugs without the hot air, which won the Transmission book prize in 2014.
Previously he has been member and Chair of the Advisory Committee on the Misuse of Drugs (ACMD – 1998-2009), President of the British Association of Psychopharmacology (BAP), President of the European College of Neuropsychopharmacology (ECNP), member of the HEFCE/NHS Senior Lecturer Selection Panel and member of the MRC Neuroscience Board. Other previous national contributions include serving as the medical expert on the Independent Inquiry into the Misuse of Drugs Act (2000 Runciman report), and membership of the Committee on Safety of Medicines, the Committee on NHS drugs and the Ministry of Defence Science Advisory Board. He was the clinical scientific lead on the 2004/5 UK Government Foresight initiative “Brain science, addiction and drugs” that provided a 25-year vision for this area of science and public policy and in 2006 he was Director of Bristol Neuroscience.
He broadcasts widely to the general public both on radio and television; highlights include being a subject for The Life Scientific on BBC radio 4, several BBC Horizon programs and the Channel 4 documentary Ecstasy-live. Additionally is much in demand for public affairs programs on therapeutic as well as illicit drugs, their harms and their classification. His also lecturers widely to the public as well as to the scientific and medical communities at the Cheltenham Science and Hay Literary Festivals, Café Scientifiques and Skeptics in the Pub. In 2010 The Times Eureka science magazine voted him one of the 100 most important figures in British Science, and the only psychiatrist in the list. In 2013 he was awarded the John Maddox Prize from Nature/Sense about Science and in 2014 his Book “Drugs: without the hot air” won the Transmission Prize for Communication of Ideas.
Declaration of Interests
- Have you, in the past three years, had patents or inventions from which you may derive personal benefit in the area of psychopharmacology?
- Have you, in the past three years, had ownership or part ownership of a company with interests in the area of psychopharmacology? (This would include holding the shares of major companies in one's own name, or those of dependent family members.)
- P1Vital, Equasy Enterprises, Alcarelle
- Have you, in the past three years, accepted a personal retainer from any company with an interest in psychopharmacology?
- Have you, in the past three years, acted as a consultant to any company with an interest in psychopharmacology?
- Lundbeck, Nalpharm, Shire, MSD, Actelion, Opiant, Orexigen, Compass, D&A Pharma, Ranvier, Mundipharma
- Have you, in the past three years, acted as an expert witness, either friendly or hostile, to any company with an interest in psychopharmacology?
- Have you, in the past three years, held a research grant from any company with an interest in psychopharmacology?
- Have you, in the past three years, had membership of the speakers' bureau for any company?
- Have you, in the past three years, accepted paid speaking engagements in industry supported symposia?
- Lundbeck, Otsuka, Lilly, BMS, Janssen, GSK, Pfizer, AstraZeneca, D&A Pharma, Servier, Martindale
- Have you, in the past three years, accepted travel or hospitality NOT related to a speaking engagement?
- Have you, in the past three years, recruited patients for industry-sponsored studies?
- If there is anything else you feel it necessary to disclose, please provide details below:
Form completed on 2nd August 2018